NEWARK, Del.--(BUSINESS WIRE)--SDIX (NASDAQ: SDIX), a leading provider of In Vitro Diagnostic (IVD) reagents, today announced its plan to introduce a new polyclonal antisera to its product line for the IVD market. The product, Apo B, will be available as antisera and in fractionated forms.
